Effect of olmesartan compared with candesartan on home blood pressure and prognostic makers of subsequent cardiovascular events in patients with essential hypertension: a single center, prospective, randomized, and open-labeled trial - Effect of olmesartan on home blood pressure and prognostic makers of cardiovascular events in patients with essential hypertension: a single center randomized trial

Chiba Kensei Hospital0 个研究点目标入组 50 人开始时间: 2011年12月21日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1. Atrial fibrillation or atrial flutter 2. History of congestive heart failure (NYHA functional class II or severer) within 6 months of enrollment 3. History of myocardial infarction, unstable angina, PTCA or CABG within 6 months of enrollment 4. History of PTA or lower extremities bypass surgery within 6 months of enrollment 5. History of cerebrovascular diseases within 6 months of enrollment 6. Plan to be performed PTCA or CABG 7. Congenital heart disease 8. sBP >=180 mmHg or dBP >=110 mmHg in a sitting position 9. Left ventricular ejection fraction <30% 10. Pregnancy or possible pregnancy 11. Hepatic dysfunction (AST and/or ALT >100 IU/l) 12. Renal dysfunction (serum creatinine >= 1.5 mg/dl) 13. Uncontrolled type 2 diabetes (HbA1c >= 8.0%) 14. Hypertensive retinopathy with hemorrhage, oozing or papilledema 15. Hyper potassium (serum potassium >= 5.5 mEq/L) 16. History of severe side effect of ARB 17. Current or history of participation (within 6 months of enrollment) in another clinical trial 18. Patients who are otherwise judged inappropriate for inclusion by the investigator

发起方

Chiba Kensei Hospital